Wednesday - April 30, 2025
Mintz Advises ArriVent BioPharma on $175M Nasdaq Initial Public Offering
February 02, 2024
BOSTON, Massachusetts, Feb. 2 -- Mintz, a law firm, issued the following news release:

Mintz advised client ArriVent BioPharma, Inc. (NASDAQ: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, on its initial public offering (IPO) on the Nasdaq Global Market.

ArriVent priced an upsized IPO of 9,722,222 shares of its common stock at a public offering price of $18.00 per share. All of the shares of . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products